DSD-C121

5α-reductase deficiency · 46,XY · DSD-C121

DSD-C121 · 5α-reductase deficiency · 2010

Genes AR, SRD5A2 · Karyotype 46,XY · Phenotypes HPO:0000047, HPO:0000054, Micropenis (HP:0000054), Hypospadias (HP:0000047)

46,XY DSD (SRD type III / Prader-like classification) caused by 5α-reductase type 2 deficiency (SRD5A2 defect).

Images · 4

Case fields and evidence

Category

5α-reductase deficiency

Age

3 days (initial) → 14.5 months (post-treatment) → 2 years (first surgery) → 4.5 years (second surgery) → 6 years (most recent follow-up)

Sex

Predominantly female phenotype at birth; the father had the name changed to a male name in the household registry; raised as male

Karyotype

46,XY

Genetics

AR, SRD5A2

Phenotypes

Micropenis (HP:0000054); Hypospadias (HP:0000047)

Diagnosis

46,XY DSD (SRD type III / Prader-like classification) caused by 5α-reductase type 2 deficiency (SRD5A2 defect).

Follow-up

Follow-up at 6 years: height dropped to 55th percentile, bone age still ~1 year advanced, growth velocity −1.2 SDS; pubic hair clearly visible; never had UTI; family satisfied with surgical result.

General phenotype

Predominantly female phenotype with ambiguous genitalia; increased shoulder hair; transient acceleration of bone age after treatment (side effect of testosterone).

Imaging

Ultrasound: no internal female genitalia; voiding cystourethrogram: urogenital sinus + distal vaginal blind end

Laboratory findings

T (pre-hCG): 0.75 ng/ml (time point: 8 days old, pre-hCG stimulation); T (post-hCG): 2.09 ng/ml (reference: normal response; time point: 72 h after hCG stimulation at 8 days); DHT (stimulated): 0.22 ng/ml (time point: 8 days); T/DHT ratio (stimulated): 9.5 (reference: <18 considered normal at the time, misleading; time point: 8 days); T (10 mo): 3.56 ng/ml (time point: recheck at 10 months); DHT (10 mo): 0.28 ng/ml (time point: 10 months); T/DHT ratio (10 mo): 12.7 (time point: 10 months); AR gene analysis: no abnormality; SRD5A2 gene: homozygous Leu55Gln (c.T164A) mutation in exon 1 (reference: both parents heterozygous carriers; time point: diagnosis); Karyotype: 46,XY normal

Management

From 3 months: IM testosterone 50 mg q3w ×4 → switched to topical DHT ointment bid–tid → penis grew to 3.5 cm; first virilizing surgery at 2 years; second surgery at 3.5 years (resection of vaginal remnant + hypospadias repair); accelerated bone age is a known side effect.

Pathology

Not reported (no gonadal biopsy performed)

Genetic variants

c.T164A

Evidence level

See source

Clinical history

See source

Perinatal history

See source

Family history

See source

Growth and development

See source

External genital examination

See source

Puberty / Tanner

See source

Limitations

See source

Cite this resource

DSD Research Library | 5α-reductase deficiency · 46,XY · DSD-C121 | v1.4.0 | 2026-11-17 | https://dsdatlas.com/en/cases/DSD-C121?version=v1.4.0